| Experimental mouse models for hepatocellular carcinoma research F Heindryckx, I Colle, H Van Vlierberghe International journal of experimental pathology 90 (4), 367-386, 2009 | 456 | 2009 |
| Angiogenesis in chronic liver disease and its complications S Coulon, F Heindryckx, A Geerts, C Van Steenkiste, I Colle, ... Liver International 31 (2), 146-162, 2011 | 356 | 2011 |
| The need for transparency and good practices in the qPCR literature SA Bustin, V Benes, J Garson, J Hellemans, J Huggett, M Kubista, ... Nature methods 10 (11), 1063-1067, 2013 | 311 | 2013 |
| Further pharmacological and genetic evidence for the efficacy of PlGF inhibition in cancer and eye disease S Van de Veire, I Stalmans, F Heindryckx, H Oura, A Tijeras-Raballand, ... Cell 141 (1), 178-190, 2010 | 303 | 2010 |
| The paradox of the unfolded protein response in cancer YP Vandewynckel, D Laukens, A Geerts, E Bogaerts, A Paridaens, ... Anticancer research 33 (11), 4683-4694, 2013 | 219 | 2013 |
| Endoplasmic reticulum stress enhances fibrosis through IRE 1α‐mediated degradation of miR‐150 and XBP‐1 splicing F Heindryckx, F Binet, M Ponticos, K Rombouts, J Lau, J Kreuger, ... EMBO molecular medicine 8 (7), 729-744, 2016 | 150 | 2016 |
| Evaluation of inflammatory and angiogenic factors in patients with non-alcoholic fatty liver disease S Coulon, S Francque, I Colle, AN Verrijken, B Blomme, F Heindryckx, ... Cytokine 59 (2), 442-449, 2012 | 148 | 2012 |
| Role of vascular endothelial growth factor in the pathophysiology of nonalcoholic steatohepatitis in two rodent models S Coulon, V Legry, F Heindryckx, C Van Steenkiste, C Casteleyn, ... Hepatology 57 (5), 1793-1805, 2013 | 102 | 2013 |
| Inhibition of placental growth factor activity reduces the severity of fibrosis, inflammation, and portal hypertension in cirrhotic mice C Van Steenkiste, J Ribera, A Geerts, M Pauta, S Tugues, C Casteleyn, ... Hepatology 53 (5), 1629-1640, 2011 | 101 | 2011 |
| Targeting the tumor stroma in hepatocellular carcinoma F Heindryckx, P Gerwins World journal of hepatology 7 (2), 165, 2015 | 95 | 2015 |
| Platelets as key factors in hepatocellular carcinoma N Pavlovic, B Rani, P Gerwins, F Heindryckx Cancers 11 (7), 1022, 2019 | 79 | 2019 |
| Role of proteoglycans in neuro-inflammation and central nervous system fibrosis F Heindryckx, JP Li Matrix Biology 68, 589-601, 2018 | 76 | 2018 |
| Kinetics of angiogenic changes in a new mouse model for hepatocellular carcinoma F Heindryckx, K Mertens, N Charette, B Vandeghinste, C Casteleyn, ... Molecular cancer 9, 1-14, 2010 | 57 | 2010 |
| The roles of transforming growth factor-β, Wnt, Notch and hypoxia on liver progenitor cells in primary liver tumours E Bogaerts, F Heindryckx, YP Vandewynckel, LA Van Grunsven, ... International Journal of Oncology 44 (4), 1015-1022, 2014 | 55 | 2014 |
| Liver cancer cell lines treated with doxorubicin under normoxia and hypoxia: Cell viability and oncologic protein profile IR Dubbelboer, N Pavlovic, F Heindryckx, E Sjögren, H Lennernäs Cancers 11 (7), 1024, 2019 | 49 | 2019 |
| Inhibiting IRE1α-endonuclease activity decreases tumor burden in a mouse model for hepatocellular carcinoma N Pavlović, C Calitz, K Thanapirom, G Mazza, K Rombouts, P Gerwins, ... Elife 9, e55865, 2020 | 38 | 2020 |
| Drug resistance and endoplasmic reticulum stress in hepatocellular carcinoma J Khaled, M Kopsida, H Lennernäs, F Heindryckx Cells 11 (4), 632, 2022 | 36 | 2022 |
| MicroRNA-24 suppression of N-deacetylase/N-sulfotransferase-1 (NDST1) reduces endothelial cell responsiveness to vascular endothelial growth factor A (VEGFA) Z Kasza, PF Fuchs, C Tamm, AS Eriksson, P O'Callaghan, F Heindryckx, ... Journal of Biological Chemistry 288 (36), 25956-25963, 2013 | 34 | 2013 |
| Macrophage depletion attenuates extracellular matrix deposition and ductular reaction in a mouse model of chronic cholangiopathies J Best, S Verhulst, WK Syn, K Lagaisse, N van Hul, F Heindryckx, ... Plos one 11 (9), e0162286, 2016 | 32 | 2016 |
| Targeting ER stress in the hepatic tumor microenvironment N Pavlović, F Heindryckx The FEBS Journal 289 (22), 7163-7176, 2022 | 31 | 2022 |
